Fusion Protein Enzyme for Biocatalytic Reduction of Cystine to Cysteine
Summary
USPTO granted patent US12600995B2 to Wacker Chemie AG for a fusion protein enzyme combining thioredoxin and thioredoxin reductase activities from E. coli to catalyze the reduction of cystine to cysteine. The patent contains 7 claims and was assigned CPC classifications related to biochemistry and peptide chemistry.
What changed
USPTO issued patent US12600995B2 to Wacker Chemie AG covering a fusion protein biocatalyst that combines thioredoxin (EC 1.8.4.8 or EC 1.8.4.10) and thioredoxin reductase (EC 1.8.1.9) activities from E. coli to reduce cystine to cysteine. The fusion protein achieves at least 100% activity compared to a mixture of the individual unfused proteins.
For pharmaceutical and biotechnology companies, this patent grant establishes exclusive intellectual property rights held by Wacker Chemie AG for this specific enzyme fusion construct. Competitors developing similar biocatalytic processes may need to design around this patent or seek licensing arrangements.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Biocatalyst as a core component of an enzyme-catalyzed redox system for the biocatalytic reduction of cystine
Grant US12600995B2 Kind: B2 Apr 14, 2026
Assignee
WACKER CHEMIE AG
Inventors
Carsten Bornhövd, Guido Jach, Ingrid Torres Monroy, Peter Welters
Abstract
An enzyme for reducing cystine to cysteine is a fusion protein that includes the protein activities of thioredoxin (protein i) having KEGG database number EC 1.8.4.8 or EC 1.8.4.10 and thioredoxin reductase (protein ii) having KEGG database number EC 1.8.1.9. The thioredoxin (protein i) is the protein activity of thioredoxin 1 from E. coli and the thioredoxin reductase (protein ii) is the protein activity of the thioredoxin reductase from E. coli. The activity of the fusion protein is at least 100% of the activity of a mixture of the same but unfused individual proteins i and ii. The fusion protein has the enzyme activity to reduce cystine to cysteine. The coding sequences (cds) responsible for the activity of protein i and ii has been fused.
CPC Classifications
C12P 13/12 C12N 9/0051 C12N 15/62 C12Y 108/01009 C12Y 108/0401 C12Y 108/04008 C07K 2319/00
Filing Date
2020-04-03
Application No.
17915538
Claims
7
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.